Portal de Periódicos da CAPES

COMPARISON OF SCREENING METHODS IN THE DETECTION OF BLADDER CANCER

1999; Lippincott Williams & Wilkins; Volume: 161; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(01)61899-8

1527-3792

Sanjay Ramakumar, Jalaluddin Bhuiyan, Jennifer A. Besse, Stefan G. E. Roberts, Peter C. Wollan, Michael L. Blute, Dennis J. O’Kane,

Telomeres, Telomerase, and Senescence

No AccessJournal of UrologyClinical Urology: Original Articles1 Feb 1999COMPARISON OF SCREENING METHODS IN THE DETECTION OF BLADDER CANCER SANJAY RAMAKUMAR, JALALUDDIN BHUIYAN, JENNIFER A. BESSE, STEVEN G. ROBERTS, PETER C. WOLLAN, MICHAEL L. BLUTE, and DENNIS J. O'KANE SANJAY RAMAKUMARSANJAY RAMAKUMAR , JALALUDDIN BHUIYANJALALUDDIN BHUIYAN , JENNIFER A. BESSEJENNIFER A. BESSE , STEVEN G. ROBERTSSTEVEN G. ROBERTS , PETER C. WOLLANPETER C. WOLLAN , MICHAEL L. BLUTEMICHAEL L. BLUTE , and DENNIS J. O'KANEDENNIS J. O'KANE View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)61899-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We prospectively evaluate and compare the sensitivity and specificity of urine cytology, BTA stat, [dagger] NMP22, [double dagger] fibrin/fibrinogen degradation products (FDP), telomerase, chemiluminescent hemoglobin and hemoglobin dipstick to detect bladder cancer. Materials and Methods: Single voided specimens were obtained from 57 patients with bladder cancer, and 139 without evidence of bladder malignancy on cystoscopy or a negative biopsy of indeterminate lesions. A cytology report was available for 125 patient and interpreted independently. BTA stat, NMP22 and FDP were analyzed according to manufacturer specifications. The telomerase assay was performed on cells collected from urine by centrifugation in preparation for polymerase chain reaction based amplification using the telomeric repeat amplification protocol assay. The chemiluminescent screening assay for hemoglobin in urine uses the pseudoperoxidase activity of hemoglobin on hydrogen peroxide and subsequent oxidation of 7-dimethylaminonaphthalene-1,2-dicarbonic acid hydrazide to generate chemiluminescence emission. Hemoglobin dipstick was interpreted as positive if the hemoglobin content in the urine was trace or greater. Results: Overall sensitivity with urine cytology, BTA stat, NMP22, FDP, telomerase, chemiluminescent, hemoglobin and the hemoglobin dipstick was 44, 74, 53, 52, 70, 67 and 47%, respectively. Specificity with cytology, telomerase and FDP was high (95, 99 and 91%, respectively) but BTA stat, NMP22 (optimized), chemiluminescent hemoglobin (optimized) and the hemoglobin dipstick demonstrated lower specificity of 73, 60, 63 and 84%, respectively. Stepwise logistic regression analysis revealed that for all tumors, and within each tumor grade and stage telomerase had the strongest association with bladder cancer among all tests (69% overall concordance). Telomerase was also positive in 91% of the patients (10 of 11) with carcinoma in situ. Conclusions: Urinary telomerase had the highest combination of sensitivity and specificity (70 and 99%, respectively) for bladder cancer screening in these patients. It was the strongest predictor with superior accuracy in patients with grade 1 and noninvasive tumors (pTa), and extremely useful in patients with carcinoma in situ. Telomerase appears to be promising and outperformed cytology, BTA stat, NMP22, FDP, chemiluminescent hemoglobin and hemoglobin dipstick in the prediction of bladder cancer. References 1 : Applications of telomerase in urologic oncology. World J. Urol.1997; 15: 120. Google Scholar 2 : Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science1945; 101: 519. Google Scholar 3 : Urine cytology of transitional cell neoplasms. Urol. Clin. N. Amer.1979; 6: 599. Google Scholar 4 : The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer1987; 60: 1423. Google Scholar 5 : Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol.1995; 154: 379. Link, Google Scholar 6 : Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology1998; 51: 44. Google Scholar 7 : Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur. Urol.1997; 32: 425. Google Scholar 8 : The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J. Urol.1997; 158: 2102. Link, Google Scholar 9 : Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology1997; 50: 49. Google Scholar 10 : Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology1997; 49: 786. Google Scholar 11 : Human bladder tumor antigen is a member of the RCA (Regulators of Complement Activation) gene family. J. Urol.1997; 157: 28. abstract 110. Google Scholar 12 : Complement factor H-related proteins are expressed in bladder cancers. Cancer Res.1997; 38: 29A. Google Scholar 13 : The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. W. J. Urol.1997; 15: 107. Google Scholar 14 : Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol.1996; 156: 1280. Link, Google Scholar 15 : Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J. Urol.1997; 158: 1899. Link, Google Scholar 16 : Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochem. Biophys. Acta1988; 948: 305. Google Scholar 17 : Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Amer. J. Path.1993; 143: 1255. Google Scholar 18 : Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res.1995; 55: 510. Google Scholar 19 : The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma. J. Urol.1984; 132: 21. Link, Google Scholar 20 : A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin-(ogen) degradation products. Cancer Res.1984; 44: 5886. Google Scholar 21 : Evaluation of biological markers in bladder cancer. J. Urol.1975; 114: 879. Link, Google Scholar 22 : Further study of fibrinogen degradation products in bladder cancer detection. Urology1978; 12: 659. Google Scholar 23 : Telomeres, telomerase and immortality. J. Natl. Cancer Inst.1995; 87: 884. Google Scholar 24 : Telomerase activity in human urothelial tumors. Amer. J. Clin. Path.1997; 107: 555. Google Scholar 25 : Telomerase activity in human bladder cancer. Clin. Cancer Res.1996; 2: 929. Google Scholar 26 : Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes. Yonsei Med. J.1997; 38: 155. Google Scholar 27 : Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl. Cancer Inst.1997; 89: 724. Google Scholar 28 : Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer1997; 79: 362. Google Scholar 29 : Tumors of the urinary tract and prostate in urinary sediment. In: . Philadelphia: J. B. Lippincott Co.1992: 951. chapt. 23. Google Scholar 30 : Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology1997; 50: 349. Google Scholar 31 : Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol.1998; 159: 394. Link, Google Scholar 32 : Specific association of human telomerase activity with immortal cells and cancer. Science1994; 266: 2011. Google Scholar 33 : New York: John Wiley and Sons, Inc.1989. Google Scholar 34 : Cancer statistics, 1998. Cancer J. Clin.1998; 48: 6. Google Scholar 35 : Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology1997; 50: 882. Google Scholar 36 : A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol.1997; 158: 801. Link, Google Scholar 37 : Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol.1997; 158: 2098. Link, Google Scholar 38 : Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer1998; 82: 708. Google Scholar 39 : Nucleic acid-based methods for the detection of cancer. Science1997; 278: 1054. Google Scholar From the Departments of Urology, Laboratory Medicine and Pathology, and Biostatistics, Mayo Graduate School of Medicine, Rochester, Minnesota(O'KANE) Requests for reprints: Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St. S. W., Rochester, Minnesota 55905.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byZuiverloon T, Tjin S, Busstra M, Bangma C, Boevé E and Zwarthoff E (2018) Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation AssayJournal of Urology, VOL. 186, NO. 2, (707-712), Online publication date: 1-Aug-2011.Tsui K, Tang P, Lin C, Chang P, Chang C and Yung B (2018) Bikunin Loss in Urine as Useful Marker for Bladder CarcinomaJournal of Urology, VOL. 183, NO. 1, (339-344), Online publication date: 1-Jan-2010.Bravaccini S, Sanchini M, Granato A, Gunelli R, Nanni O, Amadori D, Calistri D and Silvestrini R (2018) Urine Telomerase Activity for the Detection of Bladder Cancer in FemalesJournal of Urology, VOL. 178, NO. 1, (57-61), Online publication date: 1-Jul-2007.GLAS A, ROOS D, DEUTEKOM M, ZWINDERMAN A, BOSSUYT P and KURTH K (2018) Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic ReviewJournal of Urology, VOL. 169, NO. 6, (1975-1982), Online publication date: 1-Jun-2003.ATSÜ N, EKICI S, ÖGE Ö, ERGEN A, HASÇELIK G and ÖZEN H (2018) FALSE-POSITIVE RESULTS OF THE NMP22 TEST DUE TO HEMATURIAJournal of Urology, VOL. 167, NO. 2 Part 1, (555-558), Online publication date: 1-Feb-2002.BOMAN H, HEDELIN H, JACOBSSON S and HOLMÄNG S (2018) Newly Diagnosed Bladder Cancer: The Relationship of Initial Symptoms, Degree of Microhematuria and Tumor Marker StatusJournal of Urology, VOL. 168, NO. 5, (1955-1959), Online publication date: 1-Nov-2002.Friedrich M, Hellstern A, Hautmann S, Graefen M, Conrad S, Huland E and Huland H (2018) Clinical use of Urinary Markers For The Detection And Prognosis Of Bladder Carcinoma: A Comparison Of Immunocytology With Monoclonal Antibodies Against Lewis X And 486p3/12 With The BTA STAT And NMP22 TestsJournal of Urology, VOL. 168, NO. 2, (470-474), Online publication date: 1-Aug-2002.HALLING K, KING W, SOKOLOVA I, KARNES R, MEYER R, POWELL E, SEBO T, CHEVILLE J, CLAYTON A, KRAJNIK K, EBERT T, NELSON R, BURKHARDT H, RAMAKUMAR S, STEWART C, PANKRATZ V, LIEBER M, BLUTE M, ZINCKE H, SEELIG S, JENKINS R and O’KANE D (2018) A Comparison of BTA Stat, Hemoglobin Dipstick, Telomerase and Vysis Urovysion Assays for the Detection of Urothelial Carcinoma in UrineJournal of Urology, VOL. 167, NO. 5, (2001-2006), Online publication date: 1-May-2002.ÖGE Ö, KOZACI D and GEMALMAZ H (2018) THE BTA STAT TEST IS NONSPECIFIC FOR HEMATURIA: AN EXPERIMENTAL HEMATURIA MODELJournal of Urology, VOL. 167, NO. 3, (1318-1320), Online publication date: 1-Mar-2002.ZAGAYNOVA E, STRELTSOVA O, GLADKOVA N, SNOPOVA L, GELIKONOV G, FELDCHTEIN F and MOROZOV A (2018) IN VIVO OPTICAL COHERENCE TOMOGRAPHY FEASIBILITY FOR BLADDER DISEASEJournal of Urology, VOL. 167, NO. 3, (1492-1496), Online publication date: 1-Mar-2002.GIANNOPOULOS A, MANOUSAKAS T, GOUNARI A, CONSTANTINIDES C, CHOREMI-PAPADOPOULOU H and DIMOPOULOS C (2018) COMPARATIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE BTA STAT TEST, NMP22 AND URINARY BLADDER CANCER ANTIGEN FOR PRIMARY AND RECURRENT BLADDER TUMORSJournal of Urology, VOL. 166, NO. 2, (470-475), Online publication date: 1-Aug-2001.ORLANDO C, GELMINI S, SELLI C and PAZZAGLI M (2018) TELOMERASE IN UROLOGICAL MALIGNANCYJournal of Urology, VOL. 166, NO. 2, (666-673), Online publication date: 1-Aug-2001.PONSKY L, SHARMA S, PANDRANGI L, KEDIA S, NELSON D, AGARWAL A and ZIPPE C (2018) SCREENING AND MONITORING FOR BLADDER CANCER: REFINING THE USE OF NMP22Journal of Urology, VOL. 166, NO. 1, (75-78), Online publication date: 1-Jul-2001.SÁNCHEZ-CARBAYO M, URRUTIA M, SILVA J, ROMANÍ R, DE BUITRAGO J and NAVAJO J (2018) COMPARATIVE PREDICTIVE VALUES OF URINARY CYTOLOGY, URINARY BLADDER CANCER ANTIGEN, CYFRA 21-1 AND NMP22 FOR EVALUATING SYMPTOMATIC PATIENTS AT RISK FOR BLADDER CANCERJournal of Urology, VOL. 165, NO. 5, (1462-1467), Online publication date: 1-May-2001.LOKESHWAR V and SOLOWAY M (2018) CURRENT BLADDER TUMOR TESTS: DOES THEIR PROJECTED UTILITY FULFILL CLINICAL NECESSITY?Journal of Urology, VOL. 165, NO. 4, (1067-1077), Online publication date: 1-Apr-2001.VAIDYA A, SOLOWAY M, HAWKE C, TIGUERT R and CIVANTOS F (2018) DE NOVO MUSCLE INVASIVE BLADDER CANCER: IS THERE A CHANGE IN TREND?Journal of Urology, VOL. 165, NO. 1, (47-50), Online publication date: 1-Jan-2001.KONETY B and GETZENBERG R (2018) URINE BASED MARKERS OF UROLOGICAL MALIGNANCYJournal of Urology, VOL. 165, NO. 2, (600-611), Online publication date: 1-Feb-2001.CASELLA R, HUBER P, BLÖCHLINGER A, STOFFEL F, DALQUEN P, GASSER T and LEHMANN K (2018) URINARY LEVEL OF NUCLEAR MATRIX PROTEIN 22 IN THE DIAGNOSIS OF BLADDER CANCER: : EXPERIENCE WITH 130 PATIENTS WITH BIOPSY CONFIRMED TUMORJournal of Urology, VOL. 164, NO. 6, (1926-1928), Online publication date: 1-Dec-2000.HALLING K, KING W, SOKOLOVA I, MEYER R, BURKHARDT H, HALLING A, CHEVILLE J, SEBO T, RAMAKUMAR S, STEWART C, PANKRATZ S, O’KANE D, SEELIG S, LIEBER M and JENKINS R (2018) A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, VOL. 164, NO. 5, (1768-1775), Online publication date: 1-Nov-2000.Lamm D (2018) EDITORIAL: THE CHALLENGE OF IMPROVED DIAGNOSTIC AND PROGNOSTIC INDICATORS OF SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 164, NO. 3 Part 1, (690-691), Online publication date: 1-Sep-2000.RAITANEN M, MARTTILA T, KAASINEN E, RINTALA E, AINE R, TAMMELA T and TAMMELA T (2018) SENSITIVITY OF HUMAN COMPLEMENT FACTOR H RELATED PROTEIN (BTA STAT) TEST AND VOIDED URINE CYTOLOGY IN THE DIAGNOSIS OF BLADDER CANCERJournal of Urology, VOL. 163, NO. 6, (1689-1692), Online publication date: 1-Jun-2000.PARIENTE J, BORDENAVE L, JACOB F, GOBINET A, LEGER F, FERRIERE J and LE GUILLOU M (2018) ANALYTICAL AND PROSPECTIVE EVALUATION OF URINARY CYTOKERATIN 19 FRAGMENT IN BLADDER CANCERJournal of Urology, VOL. 163, NO. 4, (1116-1119), Online publication date: 1-Apr-2000. Volume 161Issue 2February 1999Page: 388-394 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information SANJAY RAMAKUMAR More articles by this author JALALUDDIN BHUIYAN More articles by this author JENNIFER A. BESSE More articles by this author STEVEN G. ROBERTS More articles by this author PETER C. WOLLAN More articles by this author MICHAEL L. BLUTE More articles by this author DENNIS J. O'KANE More articles by this author Expand All Advertisement PDF downloadLoading ...